|
Synonyms: Miraclid® | Ulinase® | Urinastatin®
ulinastatin is an approved drug (Japan, China)
Compound class:
Endogenous peptide in human, mouse or rat
Comment: Ulinastatin is considered to be a metabolite of inter-α-trypsin inhibitor (ITI) that is one of the cleavage products from the AMBP precursor protein [3]. Compared to full length ITI, ulinastatin lacks the carboxyterminal RFSN amino acids. Functionally ulinastatin is a protease inhibitor, that plays an important role in physiological and pathological processes, and has notable anti-inflammatory activity [1-2,6]. It can be purified from healthy human urine or produced using recombinant technology.
Species: Human
|
| No information available. |
Summary of Clinical Use  |
| Highly purified ulinastatin is used clinically for the treatment of acute pancreatitis [2], chronic pancreatitis, Stevens-Johnson syndrome, burns, septic shock [7], and toxic epidermal necrolysis (TEN), principally in Japan, China and India. In the EU, ulinastatin has had orphan drug designation as a treatment for acute pancreatitis since 2014. To review the history of ulinastatin's clinical evaluation click here to link to ClinicalTrials.gov's full list of ulinastatin trials. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Ulinastatin inactivates serine proteases, including trypsin, chymotrypsin, kallikrein, plasmin, granulocyte elastase, cathepsin, thrombin, and factors IXa, Xa, XIa, and XlIa. |
